Debt and Taxes: Marginal Tax Rate Changes, Capital Structure, and Innovative Activity in the Biotechnology Sector
Requires Subscription or Fee PDF

Keywords

marginal tax rates
capital structure
debt
R&D
cash flow
patenting activity
biotechnology

Abstract

The purpose of this investigation was to examine the association between changes in corporate marginal tax rates (MTRs) and measures of both innovative activity and capital structure among publicly-traded biotechnology firms.  Across a 1980-2010 time frame, a five-year distributed Almon lag model was utilized to assess the effect of annual changes in MTRs upon patenting activity, research and development (R&D) expenditures, cash and short-term investments, debt-to-asset ratios, and debt-to-equity ratios.  Across the 99 biotech firms studied, results suggested that increases in MTRs were significantly associated with marked decreases in patents, R&D expenditures, and cash and other short-term investments.  Additionally, large and statistically significant increases in both debt-to-asset and debt-to-equity ratios were observed with annual increases in MTRs.  While this research can not necessarily discern whether capital structure changes occurred either as an ex-ante response to or an ex-post result of MTR increases, the implication of decreased patenting activity warrants continued evaluations of both internal financial decision making and external tax policy.

https://doi.org/10.5912/jcb683
Requires Subscription or Fee PDF

References

Shevlin, T. (1990) Estimating corporate marginal tax rates with asymmetric tax treatment of gains and losses. Journal of the American Taxation Association 11:51-67.

Blouin J, Core JE, Guay W. (2010) Have the tax benefits of debt been overestimated? Journal of Financial Economics 98:195-213.

Graham JR. (1996a) Debt and the marginal tax rate. Journal of Financial Economics 41;41-73.

Carroll R, Holtz-Eakin D, Rider M, Rosen HS. (1999) Income taxes and entrepreneurs’ use of labor. Journal of Labor Economics 18;324-351.

Carroll R, Holtz-Eakin D, Rider M, Rosen HS. (2000) Entrepreneurs, Income Taxes, and Investment. In: Slemrod JB, ed. Does Atlas Shrug? Harvard University Press: Cambridge, MA;427-455.

Hubbard RG. (1998) Capital Market Imperfections and Investment. Journal of Economic Literature 36:157-186.

Gentry WM, Hubbard RG. (2000) Tax Policy and Entrepreneurial Entry. American Economic Review 90;283-287.

Harper DA. (2003) Foundations of Entrepreneurship and Economic Development. Routledge: New York.

Quadrini V. (2000) Entrepreneurship, saving, and social mobility. Review of Economic Dynamics 3;1-40.

Gentry WM, Hubbard RG. (1997) Why do they the wealthy save so much? Saving and investment decisions of entrepreneurs. Columbia University: New York.

Gentry WM, Hubbard RG. (2005) "Success taxes," entrepreneurial entry, and innovation. National Bureau of Economic Research: Cambridge, MA; Working Paper 10551.

Robson MT, Wren C. Marginal and average tax rates and the incentive for self-employment. Southern Economic Journal 65:757-773.

Lee Y, Gordon RH. (2005) Tax structure and economic growth. J Public Econ 89;1027-1043.

Graham JR. (2000) How big are the tax benefits of debt? Journal of Finance 55;1901-1941.

Bartholdy J, Mateus C. (2011) Debt and taxes for private firms. International Review of Financial Analysis 20;177-189.

Slemrod JB. (2000) Commentary. In: Slemrod JB, ed. Does Atlas Shrug? Harvard University Press: Cambridge, MA;456-461.

Miller M, Modigliani F. (1958) The cost of capital, corporation finance and the theory of investment. American Economic Review 48:261-297

Miller M, Modigliani F. (1961) Dividend policy, growth, and the valuation of shares. Journal of Business 34:411-433.

Hall BH. (2002) The financing of research and development. Oxford Review of Economic Policy 18;35-51.

Golec J, Vernon JA. (2009) Financial risk of the biotech industry versus the pharmaceutical industry. Applied Health Economics and Health Policy 7:155-165.

DiMasi JA, Grabowski HG. (2007) The cost of biopharmaceutical R&D: Is biotech different? Managerial and Decision Economics 28:469-479.

DiMasi JA, Hansen RW, Grabowski HG. (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics 22:151-185.

Harrington SE. Cost of capital for pharmaceutical, biotechnology and medical device firms. In: Danzon PM, Nicholson S, eds. The Oxford Handbook of the Economics of the Biopharmaceutical Industry. Oxford University Press: New York; 2012.

Barfield C, Calfee JE. (2007) Biotechnology and the Patent System. American Enterprise Institute: Washington, D.C.

Feld LP, Hechemeyer JH, Overesch M. (2011) Capital structure choice and company taxation: a meta-study. Ifo Institute, Center for Economic Studies: Munich; CESIFO Working Paper No. 3400.

Schumpeter JA. (1942) Capitalism, Socialism, and Democracy. Allen and Unwin: London.

Hall BH. (1995) The private and social returns to research and development. In: Smith BLR, and Barfield CE, eds. Technology, R&D, and the Economy. Brookings Institute and American Enterprise Institute; Washington, D.C.;140-183.

Pakes A, Griliches Z. (1984) Patents and R&D at the firm level: A first look. In: Griliches Z, editor. R&D, Patents and Productivity. University of Chicago Press: Chicago; 55-72.

Grabowski HG, Vernon J. (2000) The determinants of research and development expenditures. Journal of Evolutionary Economics 10:201-215.

Securities Exchange Commission. (2008) Division of Corporation Finance: Standard Industrial Classification (SIC) Code List. Internet: http://www.sec.gov/info/edgar/siccodes.htm.

Graham JR. (1996b) Proxies for the corporate marginal tax rate. Journal of Financial Economics 42:187-221.

Barber BM, Lyon JD. (1996) Detecting abnormal operating performance: The empirical power and specification of test statistics. Journal of Financial Economics 41:359-400.

Brooks LD, Buckmaster DA. (1976) Further evidence of the time series properties of accounting income. Journal of Finance 31:1359-1373.

Brown L. (1993) Earnings forecasting research: its implications for capital market research. International Journal of Forecasting 9:295-320.

Hayn C. (1995) The information content of losses. Journal of Accounting and Economics 20:125-53.

Almon S. (1965) The distributed lag between capital appropriations and net expenditures. Econometrica 33:178-196.

Skrepnek GH, Olvey EL, Sahai A. (2012) Econometric approaches in evaluating cost and utilization within pharmacoeconomic analyses. Pharmaceutical Policy and Law 14:105-122.

Pan W, Connett JE. (2002) Selecting the working correlation structure in generalized estimating equations with application to the lung health study. Statistica Sinica 12:475-490.

Liang KY, Zeger SL. (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13-22.

Alti A. (2003) How sensitive is investment to cash flow when financing is frictionless? The Journal of Finance 58:707-722.

Hines JR. (2001) Corporate Taxation. University of

Michigan and National Bureau of Economic Research: Cambridge, MA.

Brown JR, Fazzari SM, Petersen BC. (2009) Financing innovation and growth: cash flow, external equity, and the 1990s R&D boom. Journal of Finance. 1;151-185.

Hall EU, Vezzulli A. (2008) Guarantee-backed loans and R&D investments. Do mutual guarantee consortiums value R&D? Università Commerciale Luigi:Bocconi–Milano; Working paper 227.

Carpenter RE, Petersen BC. (2002) Capital market imperfections, high-tech investment, and new equity financing. Economic Journal 112:54-72.

Skrepnek GH. (2004) Accounting- versus economic-based rates of return: implications for profitability measures in the pharmaceutical industry. Clinical Therapeutics 26:155-174.

Nicholson S. (2012) Financing research and development. In: Danzon PM, Nicholson S, eds. The Oxford Handbook of the Economics of the Biopharmaceutical Industry. Oxford University Press: New York.

Berger AN, Udell GF. (1990) Collateral, loan quality, and bank risk. Journal of Monetary Economics 25:21-42.

Loumioti M. (2012) The use of intangible assets as loan collateral. University of Southern California: Los Angeles.

Grabowski HG, Vernon JM. (1981) The determinants of R&D expenditures. In: Helms RB, ed. Drugs and Health. American Enterprise Institute: Washington D.C.

Vernon JA. (2005) Examining the link between price regulation and pharmaceutical R&D investment. Health Economics. 14:1-17.

Myers SC, Majluf NS. (1984) Corporate financing and investment decisions when firms have information that investors do not have. Journal of Financial Economics 13:187-221.

Myers SC. (2000) Outside equity. Journal of Finance 55;1005-1037.

Ou C, Haynes GW. (2006) Acquisition of additional equity capital by small firms: Findings from the national survey of small business finances. Small Business Economics 27:157-168.

Vos E, Yeh AJ, Carter S, Tagg S. (2007) The happy story of small business financing. Journal of Banking & Finance 31:2648-2672.

Cummins JG, Hassett KA. Hubbard RG. (1994) Reconsideration of investment behavior using tax reforms as natural experiments. Brookings Papers on Economic Activity 2:1-74.

Hassett KA, Hubbard RG. (1997) Tax policy and investment. In: Auerbach A, ed. Fiscal Policy: Lessons from the Literature. MIT Press: Cambridge, MA; 339-385.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.